20 / 62
2
PFS (Investigator Assessed)
No. at risk
Atezolizumab 201 190 178 158 147 98 58 48 41 32 29 26 21 15 12 11 3 3 2 2 1 1
Placebo
202 193 184 167 147 80 44 30 25 23 16 15 9 9 6 5 3 3
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
100
90
80
70
60
50
40
30
20
10
0
Atezolizumab
+ CP/ET
Placebo
+ CP/ET
Censored
+
Atezolizumab
+ CP/ET
(N = 201)
Placebo
+ CP/ET
(N = 202)
PFS events — no. (%)
171 (85.1)
189 (93.6)
Median PFS — months (95%
CI)
5.2
(4.4, 5.6)
4.3
(4.2, 4.5)
HR (95% CI)
0.77
(0.62, 0.96)
p = 0.017
Median follow-up, months
13.9
Clinical data cut-off date: April 24, 2018, 11 months after the last patient was enrolled. CI, confidence interval. HR, hazard ratio; CP/ET, carboplatin + etoposide.
Adapted from The New England Journal of Medicine, Horn L, et al, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, Epub ahead of
print.
Months
6-month PFS
12-month PFS
30.9%
22.4%
5.4%
12.6%
Progression-free survival (%)